Bausch & Lomb takes posterior uveitis implant to the US
This article was originally published in Clinica
The US FDA has given Bausch & Lomb (B&L) the all-clear to market its eye implant for treating the sight-threatening inflammatory disease, posterior uveitis.
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
No device-related warning letters were released by the US FDA the week of 19 February.
Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.